IL-6 receptor blockade ameliorates diabetic nephropathy via inhibiting inflammasome in mice

Metabolism: Clinical and Experimental

Volumn 83, Issue , 2018, Pages 18-24

  Wu, Rui ^a   Liu, Xuanchen ^a   Yin, Jianyong ^a   Wu, Huijuan ^b   Cai, Xiulei ^c   Wang, Niansong ^a   Qian, Youcun ^d   Wang, Feng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b FUDAN UNIVERSITY   (China)

^c QINGDAO AGRICULTURAL UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Biologics; IL 17A; IL 6; Inflammation; NLRP3 inflammasome; Tocilizumab

Indexed keywords

CRYOPYRIN; GLUCOSE; HEMOGLOBIN A1C; IMMUNOGLOBULIN G1 ANTIBODY; INSULIN; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; ISOPHANE INSULIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOCILIZUMAB; INFLAMMASOME; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEMOGLOBIN BLOOD LEVEL; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; MESANGIUM CELL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEINURIA; RECEPTOR BLOCKING; RENAL PROTECTION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; COMPLICATION; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; INFLAMMASOMES; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, INTERLEUKIN-6;

EID: 85042202027     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2018.01.002     Document Type: Article

References (41)

1. Ashcroft, F.M., Rorsman, P., Diabetes mellitus and the beta cell: the last ten years. Cell 148 (2012), 1160–1171.
2. Upadhyay, J., Polyzos, S.A., Perakakis, N., Thakkar, B., Paschou, S.A., Katsiki, N., et al. Pharmacotherapy of type 2 diabetes: an update. Metabolism 78 (2018), 13–42.
3. Oltean, S., Qiu, Y., Ferguson, J.K., Stevens, M., Neal, C., Russell, A., et al. Vascular endothelial growth factor-A165b is protective and restores endothelial glycocalyx in diabetic nephropathy. J Am Soc Nephrol 26 (2015), 1889–1904.
4. Wada, J., Makino, H., Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) 124 (2013), 139–152.
5. Suzuki, D., Miyazaki, M., Naka, R., Koji, T., Yagame, M., Jinde, K., et al. In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 44 (1995), 1233–1238.
6. Dalla, V.M., Mussap, M., Gallina, P., Bruseghin, M., Cernigoi, A.M., Saller, A., et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 16:Suppl. 1 (2005), S78–S82.
7. Kim, D.I., Park, S.H., Sequential signaling cascade of IL-6 and PGC-1alpha is involved in high glucose-induced podocyte loss and growth arrest. Biochem Biophys Res Commun 435 (2013), 702–707.
8. Kaur, H., Chien, A., Jialal, I., Hyperglycemia induces Toll like. receptor 4 expression and activity in mouse mesangial cells: Relevance to diabetic nephropathy. Am J Physiol Renal Physiol 303 (2012), F1145–F1150.
9. Ruef, C., Budde, K., Lacy, J., Northemann, W., Baumann, M., Sterzel, R.B., et al. Interleukin 6 is an autocrine growth factor for mesangial cells. Kidney Int 38 (1990), 249–257.
10. Yao, Y., Chen, S., Cao, M., Fan, X., Yang, T., Huang, Y., et al. Antigen-specific CD8+ T cell feedback activates NLRP3 inflammasome in antigen-presenting cells through perforin. Nat Commun, 8, 2017, 15402.
11. Lee, H.M., Kim, J.J., Kim, H.J., Shong, M., Ku, B.J., Jo, E.K., Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 62 (2013), 194–204.
12. Shahzad, K., Bock, F., Dong, W., Wang, H., Kopf, S., Kohli, S., et al. Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int 87 (2015), 74–84.
13. Rheinheimer, J., de Souza, B.M., Cardoso, N.S., Bauer, A.C., Crispim, D., Current role of the NLRP3 inflammasome on obesity and insulin resistance: a systematic review. Metabolism 74 (2017), 1–9.
14. Qiu, Y.Y., Tang, L.Q., Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy. Pharmacol Res 114 (2016), 251–264.
15. Yamaguchi, K., Nishimura, T., Ishiba, H., Seko, Y., Okajima, A., Fujii, H., et al. Blockade of interleukin 6 signalling ameliorates systemic insulin resistance through upregulation of glucose uptake in skeletal muscle and improves hepatic steatosis in high-fat diet fed mice. Liver Int 35 (2015), 550–561.
16. Cai, D., Yuan, M., Frantz, D.F., Melendez, P.A., Hansen, L., Lee, J., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11 (2005), 183–190.
17. Wunderlich, F.T., Strohle, P., Konner, A.C., Gruber, S., Tovar, S., Bronneke, H.S., et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab 12 (2010), 237–249.
18. Matthews, V.B., Allen, T.L., Risis, S., Chan, M.H., Henstridge, D.C., Watson, N., et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 53 (2010), 2431–2441.
19. Chen, K.L., Lv, Z.Y., Yang, H.W., Liu, Y., Long, F.W., Zhou, B., et al. Effects of tocilizumab on experimental severe acute pancreatitis and associated acute lung injury. Crit Care Med 44 (2016), e664–e677.
20. Fujita, H., Fujishima, H., Koshimura, J., Hosoba, M., Yoshioka, N., Shimotomai, T., et al. Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice. Endocr J 52 (2005), 427–433.
21. Maki, T., Maeda, Y., Sonoda, N., Makimura, H., Kimura, S., Maeno, S., et al. Renoprotective effect of a novel selective PPARalpha modulator K-877 in db/db mice: a role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway. Metabolism 71 (2017), 33–45.
22. Wang, F., Zhang, G., Lu, Z., Geurts, A.M., Usa, K., Jacob, H.J., et al. Antithrombin III/SerpinC1 insufficiency exacerbates renal ischemia/reperfusion injury. Kidney Int 88 (2015), 796–803.
23. Yin, J., Lu, Z., Wang, F., Jiang, Z., Lu, L., Miao, N., et al. Renalase attenuates hypertension, renal injury and cardiac remodelling in rats with subtotal nephrectomy. J Cell Mol Med 20 (2016), 1106–1117.
24. Lu, Z., Cheng, D., Yin, J., Wu, R., Zhang, G., Zhao, Q., et al. Antithrombin III protects against contrast-induced nephropathy. EBioMedicine 17 (2017), 101–107.
25. Lv, M., Chen, Z., Hu, G., Li, Q., Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives. Drug Discov Today 20 (2015), 332–346.
26. Chen, X., Wu, R., Kong, Y., Yang, Y., Gao, Y., Sun, D., et al. Tanshinone IIA attenuates renal damage in STZ-induced diabetic rats via inhibiting oxidative stress and inflammation. Oncotarget 8 (2017), 31915–31922.
27. King, A., Bowe, J., Animal models for diabetes: understanding the pathogenesis and finding new treatments. Biochem Pharmacol 99 (2016), 1–10.
28. Powell, N., Lo, J.W., Biancheri, P., Vossenkamper, A., Pantazi, E., Walker, A.W., et al. Interleukin 6 increases production of cytokines by colonic innate lymphoid cells in mice and patients with chronic intestinal inflammation. Gastroenterology 149 (2015), 456–467.
29. Zhang, S., Yu, N., Zhang, R., Zhang, S., Wu, J., Interleukin-17A induces IL-1beta secretion from RPE cells via the NLRP3 inflammasome. Invest Ophthalmol Vis Sci 57 (2016), 312–319.
30. Lu, Z., Liu, N., Wang, F., Epigenetic regulations in diabetic nephropathy. J. Diabetes Res., 2017, 2017, 7805058.
31. Wu, R., Kong, Y., Yin, J., Liang, R., Lu, Z., Wang, N., et al. Antithrombin iii is a novel predictor for contrast induced nephropathy after coronary angiography: An observational, cross-sectional study. Kidney Blood Press Res 43 (2018), 170–180.
32. Saraheimo, M., Teppo, A.M., Forsblom, C., Fagerudd, J., Groop, P.H., Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 46 (2003), 1402–1407.
33. Wang, F., Huang, B., Li, J., Liu, L., Wang, N., Renalase might be associated with hypertension and insulin resistance in type 2 diabetes. Ren Fail 36 (2014), 552–556.
34. Campbell, I.L., Kay, T.W., Oxbrow, L., Harrison, L.C., Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest 87 (1991), 739–742.
35. Ogata, A., Morishima, A., Hirano, T., Hishitani, Y., Hagihara, K., Shima, Y., et al. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis 70 (2011), 1164–1165.
36. Mirjafari, H., Ruperto, N., Brunner, H., Zuber, Z., Zulian, F., Maldonado-Velázquez, M., et al. Insulin sensitivity is improved in sjia children with insulin resistance after tocilizumab treatment: results from the tender study. Pediatr Rheumatol, 11(Suppl. 2), 2013, O23.
37. Kimura, A., Kishimoto, T., IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40 (2010), 1830–1835.
38. Serada, S., Fujimoto, M., Mihara, M., Koike, N., Ohsugi, Y., Nomura, S., et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 105 (2008), 9041–9046.
39. Cortvrindt, C., Speeckaert, R., Moerman, A., Delanghe, J.R., Speeckaert, M.M., The role of interleukin-17A in the pathogenesis of kidney diseases. Pathology 49 (2017), 247–258.
40. Kim, S.M., Lee, S.H., Lee, A., Kim, D.J., Kim, Y.G., Kim, S.Y., et al. Targeting T helper 17 by mycophenolate mofetil attenuates diabetic nephropathy progression. Transl Res 166 (2015), 375–383.
41. Kim, S.R., Kim, H.J., Kim, D.I., Lee, K.B., Park, H.J., Jeong, J.S., et al. Blockade of interplay between IL-17A and endoplasmic reticulum stress attenuates LPS-induced lung injury. Theranostics 5 (2015), 1343–1362.